Meeting Banner
Abstract #2406

Analysis of liver function after molecular targeting therapy of HCC with hepatocyte fraction index obtained from gadoxetic acid-enhanced MRI.

Yudai Syogan1, Satoshi Kobayashi1, Yu Ueda2, Noboru Taniguchi1, Naoki Ohno1, Tosiaki Miyati1, Toshifumi Gabata3, Takeshi Terashima4, Kuniaki Arai4, and Tatsuya Yamashita4
1Quantum Medical Technology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, 2Philips.Japan, Tokyo, Japan, 3Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, 4Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

Hepatocyte fraction index (HeFra index) obtained from gadoxetic acid-enhanced MR imaging might be possible surrogate marker of liver function after molecular targeting therapy to advanced HCC, and the molecular targeting therapy to advanced HCC do not affect the function of background liver parenchyma.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here